China’s Research on COVID-19—Clinical Medicine
No.4 June 24, 2020
Quality clinical treatments and drugs are crucial to reduce severe cases of COVID-19 and mortality rates.
As of June 20, Chinese scholars had registered 573 clinical trials and published 1,831 journal articles on COVID-19. The research topics of these articles include early warning indicators of severe cases, the clinical management of cases, the in vitro selection of antiviral drugs and related clinical experiments, convalescent plasma therapy and immunotherapy drugs.
On this basis, China has issued a series of clinical treatment guidelines and experts’ consensus statements, including COVID-19 diagnosis and treatment plan; expert consensus statement on diagnosis and treatment of severe and critical COVID-19 cases; diagnosis, treatment and prevention of COVID-19 infection in children and the elderly; and treatment of COVID-19 with chloroquine phosphate.
Wenhao Dai’s group published an article in Science, titled “Structure-based design of antiviral drug candidates targeting the SARS-CoV-2”, which reported that the group has designed and synthesized two lead compounds (11a and 11b) targeting Mpro. Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. Both compounds showed good pharmacokinetic properties in vivo, which suggests that these compounds are promising drug candidates.
A study by Ivan Fan-Ngai Hung’s group published in The Lancet, titled “Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial”, reported that 127 patients were recruited, of whom 86 were randomly assigned to the combination test group and 41 were assigned to the control group. They found that early triple antiviral therapy was safe and superior to lopinavir–ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19.